Clinical Trials

494 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07415031 2026-04-08

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Other solid neoplasm

Solid Tumors

NCT07513324 2026-04-07

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

116 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07509099 2026-04-03

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

316 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07264075 2026-04-02

ILLUMINE

780 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07486817 2026-03-23

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

60 enrolled

Lung Neoplasms

NCT07484139 2026-03-20

NEO COMBAT XL

26 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07486687 2026-03-20

PLANET

1,000 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07021989 2026-03-17

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

38 enrolled

Lymphoid

Hodgkin Disease

NCT07475572 2026-03-16

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Phase 1/2 Not yet recruiting

120 enrolled

Dermatologic

Melanoma

NCT07469774 2026-03-13

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

111 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT07452224 2026-03-12

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07466927 2026-03-12

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

30 enrolled

HER2-negative Breast Cancer

NCT07460206 2026-03-10

PRELUDE

108 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07409844 2026-02-20

RESET C2

152 enrolled

Gastrointestinal

Colonic Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT05741164 2026-02-17

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

37 enrolled

Triple Negative Breast Neoplasms

NCT07412054 2026-02-17

BLP-HCC

234 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

30 enrolled

Triple Negative Breast Neoplasms

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07360743 2026-02-10

META-1

275 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07385846 2026-02-04

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

8 enrolled

CNS

Turcot syndrome, Glioblastoma

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

718 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04266730 2026-01-28

PANDA-VAC

6 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Phase 2/3 Not yet recruiting

87 enrolled

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT07365319 2026-01-26

TeLuRide-008

750 enrolled